Wed Aug 18 2021

suPAR (cut-off levels ⩽4, 4-6, and ⩾6 ng/mL) can predict the need for mechanical ventilation and mortality in patients with COVID-19 symptoms.

suPAR is a biomarker associated with adverse outcomes. This study aimed to investigate the associations between plasma suPAR levels (testing the cut-offs ⩽4, 4-6, and ⩾6 ng/mL) with risk of 14-day mortality, and with the risk of mechanical ventilation in patients that tested positive for SARS-CoV-2.

This observational cohort study of 386 patients presenting symptoms of COVID-19 at the Department of Emergency Medicine, Amager and Hvidovre Hospital, Denmark from March 19th, 2020 to April 3rd, 2020, found suPAR levels predictive of mortality and the need for mechanical ventilation.

Validation of the findings was carried out in a similar-sized COVID-19 patient cohort from Mikkeli Central Hospital, Finland.

Conclusions:

Patients with symptoms of COVID-19 and suPAR ⩽4 or ⩾6 ng/mL had low or high risk, respectively, concerning the need for mechanical ventilation or mortality.

Other studies supporting this cut-off

1: Santeri Seppälä, Andreas Peter Andersen, Kristiina Nyyssönen et al. suPAR Cut-offs for Stratification of Low, Medium, and High-risk Acute Medical Patients in the Emergency Department, 26 May 2021, PREPRINT (Version 1) available at Research Square. https://www.researchsquare.com/article/rs-542503/v1
2: Altintas, I., Eugen-Olsen, J., Seppälä, S., Tingleff, J., Stauning, M. A., El Caidi, N. O., Elmajdoubi, S., Gamst-Jensen, H., Lindstrøm, M. B., Rasmussen, L. J. H., Kristiansen, K. T., Rasmussen, C., Nehlin, J. O., Kallemose, T., Hyppölä, H., & Andersen, O. (2021). suPAR Cut-Offs for Risk Stratification in Patients With Symptoms of COVID-19. Biomarker Insights. https://journals.sagepub.com/doi/full/10.1177/11772719211034685 

900+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 4 products:

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

suPARnostic POC+

POC+

Point-of-care finger prick

suPAR is used in clinical routine in 48 hospitals

48 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling.
This period covers January 1, 2022, until December 31, 2022. Some hospital locations cannot be disclosed due to confidentiality.

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates